You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 673 FIERCE-HN: a multicenter, randomized, placebo-controlled, phase 3 study of ficlatuzumab + cetuximab in pts w/recurrent or metastatic (R/M) HPV-negative head and neck squamous cell carcinoma (HNSCC)

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Clinical Trial In Progress
673 FIERCE-HN: a multicenter, randomized, placebo-controlled, phase 3 study of ficlatuzumab + cetuximab in pts w/recurrent or metastatic (R/M) HPV-negative head and neck squamous cell carcinoma (HNSCC)

 

Online download statistics by month:

Online download statistics by month: November 2023 to June 2025

AbstractFullPdf
Nov 2023188025
Dec 20234207
Jan 20244504
Feb 202484013
Mar 20246802
Apr 20245609
May 20242003
Jun 20244002
Jul 202490026
Aug 202468011
Sep 202410805
Oct 202448015
Nov 202448012
Dec 202410008
Jan 2025122015
Feb 20254407
Mar 20250016
Apr 2025004
May 2025009
Jun 2025005
Total11710198